TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque

Neuropharmacology

Volumn 73, Issue , 2013, Pages 337-347

  Johnston, Tom H ^a   Huot, Philippe ^a,b   Fox, Susan H ^a,e   Koprich, James B ^b   Szeliga, Kendall T ^a,d   James, John W ^c,f   Graef, John D ^c   Letchworth, Sharon R ^c   Jordan, Kristen G ^c   Hill, Michael P ^a,d   Brotchie, Jonathan M ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TARGACEPT INC   (United States)

^d Atuka Inc   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Dyskinesia; MPTP; NAchR; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; TC 8831; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDYSKINETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CHOREA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FEMALE; MACACA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION;

DYSKINESIA; MPTP; NACHR; PRIMATE;

AMANTADINE; ANIMALS; AZABICYCLO COMPOUNDS; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MPTP POISONING; NICOTINIC AGONISTS;

EID: 84884629648     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.06.005     Document Type: Article

References (43)

1. Blanchet, P.J., Konitsiotis, S., Chase, T.N., 1998. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13, 798-802.
2. Bordia, T., Campos, C., Huang, L., Quik, M., 2008. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 327, 239-247.
3. Bordia, T., Campos, C., McIntosh, J.M., Quik, M., 2010. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther. 333, 929-938.
4. Buck, K., Ferger, B., 2010. L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov. Today 15, 867-875.
5. Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., Durif, F., 2005. Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. 20, 224-230.
6. Fabbrini, G., Brotchie, J.M., Grandas, F., Nomoto, M., Goetz, C.G., 2007. Levodopa-induced dyskinesias. Mov. Disord. 22, 1379-1389.
7. Fox, S.H., Kellett, M., Moore, A.P., Crossman, A.R., Brotchie, J.M., 2002. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17, 145-149.
8. Goetz, C.G., Poewe, W., Rascol, O., Sampaio, C., 2005. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 20, 523-539.
9. Gomez-Ramirez, J., Johnston, T.H., Visanji, N.P., Fox, S.H., Brotchie, J.M., 2006. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 21, 839-846.
10. * receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci. 30, 5311-5325.
11. Holladay, M.W., Dart, M.J., Lynch, J.K., 1997. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40, 4169-4194.
12. Huang, L.Z., Campos, C., Ly, J., Ivy Carroll, F., Quik, M., 2011a. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60, 861-868.
13. * nicotinic receptors. J. Pharmacol. Exp. Ther. 338, 932-941.
14. Huot, P., Johnston, T.H., Koprich, J.B., Fox, S.H., Brotchie, J.M., 2012. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology 63, 829-836.
15. Huot, P., Johnston, T.H., Snoeren, T., Koprich, J.B., Hill, M.P., Fox, S.H., Brotchie, J.M., 2013. Use of catechol-O-methyltransferase inhibition to minimize L-3, 4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-lesioned macaque. Eur. J. Neurosci. 37, 831-838.
16. Inc, N.P., 2010. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease.
17. Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals, N, 1996. Guide for the Care and Use of Laboratory Animals. U.S. Dept. of Health and Human Services, Public Health Service, Bethesda, Md.
18. Johnston, T.H., Fox, S.H., McIldowie, M.J., Piggott, M.J., Brotchie, J.M., 2010a. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333, 865-873.
19. Johnston, T.H., Fox, S.H., Piggott, M.J., Savola, J.M., Brotchie, J.M., 2010b. The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov. Disord. 25, 2084-2093.
20. Kaiser, S., Wonnacott, S., 2000. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58, 312-318.
21. Letchworth, S.R., Whiteaker, P., 2011. Progress and challenges in the study of alpha6-containing nicotinic acetylcholine receptors. Biochem. Pharmacol. 82, 862-872.
22. Lewitt, P.A., Hauser, R.A., Lu, M., Nicholas, A.P., Weiner, W., Coppard, N., Leinonen, M., Savola, J.M., 2012. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79, 163-169.
23. Lubarr, N., Bressman, S., 2011. Treatment of generalized dystonia. Curr. Treat Options Neurol. 13, 274-289.
24. Meissner, W.G., Frasier, M., Gasser, T., Goetz, C.G., Lozano, A., Piccini, P., Obeso, J.A., Rascol, O., Schapira, A., Voon, V., Weiner, D.M., Tison, F., Bezard, E., 2011. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 10, 377-393.
25. Muller, T., Olanow, C.W., Nutt, J., Hicking, C., Laska, E., Russ, H., 2006. The paddy-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in PD patients. Mov. Disord. 21, S591.
26. Nomoto, M., Thompson, P.D., Sheehy, M.P., Quinn, N.P., Marsden, C.D., 1987. Anticho-linergic-induced chorea in the treatment of focal dystonia. Mov. Disord. 2, 53-56.
27. Pahwa, R., Factor, S.A., Lyons, K.E., Ondo, W.G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., Weiner, W.J., Quality Standards Subcommittee of the American Academy of, N, 2006. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 983-995.
28. Papa, S.M., Chase, T.N., 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39, 574-578.
29. * nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol. Pharmacol. 78, 971-980.
30. Poewe, W., 2009. Treatments for Parkinson diseaseepast achievements and current clinical needs. Neurology 72, S65-S73.
31. * nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 63, 938-966.
32. Quik, M., Vailati, S., Bordia, T., Kulak, J.M., Fan, H., McIntosh, J.M., Clementi, F., Gotti, C., 2005. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine or L-DOPA. Mol. Pharmacol. 67, 32-41.
33. Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J.W., Di Monte, D., 2007. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol. 62, 588-596.
34. Quik, M., O'Leary, K., Tanner, C.M., 2008. Nicotine and Parkinson's disease: implications for therapy. Mov. Disord. 23, 1641-1652.
35. Quik, M., Park, K.M., Hrachova, M., Mallela, A., Huang, L.Z., McIntosh, J.M., Grady, S.R., 2012. Role for alpha6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63, 450-459.
36. Quik, M., Campos, C., Bordia, T., Strachan, J.P., Zhang, J., McIntosh, J.M., Letchworth, S., Jordan, K., 2013a. alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 71, 191-203.
37. Quik, M., Mallela, A., Chin, M., McIntosh, J.M., Perez, X.A., Bordia, T., 2013b. Nicotine-mediatedimprovementin L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol. Dis. 50, 30-41.
38. Rascol, O., Damier, P., Goetz, C.G., Hicking, C., Hock, K., Muller, T., Olanow, C.W., Russ, H., 2006. A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-dopa-induced dyskinesia associated with Parkinson's disease: the Paddy-1 study. Mov. Disord. 21, S492-S493.
39. Rupniak, N.M., Boyce, S., Steventon, M.J., Iversen, S.D., Marsden, C.D., 1992. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann. Neurol. 32, 103-105.
40. Salminen, O., Murphy, K.L., McIntosh, J.M., Drago, J., Marks, M.J., Collins, A.C., Grady, S.R., 2004. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65, 1526-1535.
41. Thomas, A., Iacono, D., Luciano, A.L., Armellino, K., Di Iorio, A., Onofrj, M., 2004. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 75, 141-143.
42. Verhagen Metman, L., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M.M., Chase, T.N., 1998. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1326.
43. Visanji, N.P., Fox, S.H., Johnston, T.H., Millan, M.J., Brotchie, J.M., 2009. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-lesioned macaques. J. Pharmacol. Exp. Ther. 328, 276-283.